Info

🌱 來自：regimen-of-management_of_diffuse_large_b-cell_lymphoma

daepoch-r

1.Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. The Lancet Haematology. 2018;5(12):e609-e617. doi:10.1016/S2352-3026(18)30177-7

• Design: Phase III trial

• Number of patients: 491

• Patients characteristics: Most patients (74%) had stage III or IV disease; International Prognostic Index (IPI) risk groups included 26% IPI 0 to 1, 37% IPI 2, 25% IPI 3, and 12% IPI 4 to 5

• Agent:

  • Intervention: DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab)
  • Control: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)

• Treatment line: Frontline therapy for diffuse large B-cell lymphoma

• Trial Acronym or NCTId Number: Alliance/CALGB 50303 (NCT00118209)

• Comparison of outcomes:

  2y Outcome	DA-EPOCH-R	R-CHOP
  Progression-free Survival	78.9%	75.5%
  Overall Survival	86.5%	85.7%
  Response Rate	not reported	not reported